0.81
-0.0402(-4.73%)
Currency In USD
| Previous Close | 0.85 |
| Open | 0.82 |
| Day High | 0.86 |
| Day Low | 0.8 |
| 52-Week High | 2.79 |
| 52-Week Low | 0.32 |
| Volume | 319,741 |
| Average Volume | 3.73M |
| Market Cap | 58.27M |
| PE | -0.6 |
| EPS | -1.34 |
| Moving Average 50 Days | 0.77 |
| Moving Average 200 Days | 1.21 |
| Change | -0.04 |
If you invested $1000 in IO Biotech, Inc. (IOBT) since IPO date, it would be worth $51.75 as of December 14, 2025 at a share price of $0.81. Whereas If you bought $1000 worth of IO Biotech, Inc. (IOBT) shares 3 years ago, it would be worth $269.97 as of December 14, 2025 at a share price of $0.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IO Biotech Announces Participation in Upcoming December Investor Conferences
GlobeNewswire Inc.
Nov 26, 2025 3:46 PM GMT
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the Company’s participation in the 8th
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
GlobeNewswire Inc.
Nov 07, 2025 2:00 PM GMT
Pre-clinical data for IO Biotech’s next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted modulation of immunosuppressive myel
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
GlobeNewswire Inc.
Oct 20, 2025 6:30 AM GMT
Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS) primary endpoint for statistic